Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance aflibercept after first-line FOLFIRI + aflibercept in metastatic colorectal cancer
2013-002567-26Phase 2Completed
- Sponsor
- HeCOG
- Start
- Mar 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in metastatic colorectal adenocarcinoma (mCRC), sponsored by HeCOG. Primary endpoint: Progression-free survival rate at 1 year. Started Mar 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2013-002567-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002567-26.